ADV100 is a drug that has significant anti inflammatory and anti-fibrotic actions . It thus has therapeutic potential in reducing ocular surface disease secondary to tear deficiency induced by conditions such as ocular GVHD, Stevens Jonson syndrome and Sjogrens syndrome. Dry eye disease is seen with increased prevalence in patients with autoimmune diseases, which affect approximately 8% of the population, of whom 78% are women.
ADV200 is a monoclonal antibody that significantly inhibits Meibomian Gland apoptosis and atrophy. It thus has therapeutic potential in reducing evaporative dry eye disease due to Meibomian Gland Dysfunction (MGD). Meibomian gland dysfunction may result in alterations of the tear film, symptoms of eye irritation, clinically apparent inflammation and ocular surface disease. Additionally, MGD may well be the leading cause of Dry Eye Disease globally.
ADV300 is a Unified Clinical Trials Management Platform for data driven decision making to deliver precision and high-quality clinical development services from feasibility studies, patient enrollment optimization to maintaining trials at any stage from phase I, II, III, IV until filing.